“We will continue to pursue legal action against those who provide potentially unsafe and ineffective compounded ‘semaglutide’ products and knowingly deceive patients who are seeking treatment, thereby eroding public trust in the safety of FDA-approved medicines,” said Doug Langa, executive vice president, North America operations and president of Novo Nordisk.
Fed. Judge Approves Settlement, Fees Against St. Louis Firm’s Data Breach
U.S. Magistrate Judge John M. Bodenhausen of the Eastern District